Redburn Atlantic Sets Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) Stock to “a Buy”
Redburn Atlantic raised the price target for the Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) stock to “a Buy”. The rating was released on Jun-28-24, according to finviz. The research report from Wolfe Research has initiated the stock to Outperform, with a price target set at $515. The stock was downgraded by Evercore ISI, who disclosed in a […]
Does A Technical Metric Suggest That Vertex Pharmaceuticals, Inc. (VRTX) Stock Is Ready To Rise?
Evercore ISI raised the price target for the Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) stock from “an In-line” to “an Outperform”. The rating was released on April 11, 2024, according to finviz. The research report from Evercore ISI has downgraded the stock from Outperform to In-line, with a price target set at $438. In their research brief […]
The future of Vertex Pharmaceuticals, Inc. (VRTX) Stock is still in tatters?
Evercore ISI raised the price target for the Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) stock from “an In-line” to “an Outperform”. The rating was released on April 11, 2024, according to finviz. The research report from Evercore ISI has downgraded the stock from Outperform to In-line, with a price target set at $438. In their research brief […]
Does Vertex Pharmaceuticals, Inc. (VRTX) Stock have plenty of room for growth?
Evercore ISI raised the price target for the Vertex Pharmaceuticals, Inc. (NASDAQ:VRTX) stock from “an In-line” to “an Outperform”. The rating was released on April 11, 2024, according to finviz. The research report from Evercore ISI has downgraded the stock from Outperform to In-line, with a price target set at $438. In their research brief […]
